Cannabinoid/opioid crosstalk in the central nervous system

Critical Reviews in Neurobiology

Volumn 16, Issue 1-2, 2004, Pages 159-172

  Corchero, Javier ^a   Manzanares, Jorge ^b   Fuentes, José A ^c  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Anxiety; Cannabinoids; Drug abuse; Nociception; Opioid cannabinoid interactions; Opioids

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; AMPHETAMINE; BUSPIRONE; CANNABINOID; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; COCAINE; DRONABINOL; NICOTINE; OPIATE; RIMONABANT; SEROTONIN 1A AGONIST;

ANTINOCICEPTION; ANXIETY; CENTRAL NERVOUS SYSTEM; DNA MODIFICATION; NONHUMAN; REINFORCEMENT; REVIEW;

ANIMALS; ANXIETY; CANNABINOIDS; HUMANS; NARCOTICS; PAIN; PAIN MEASUREMENT; RECEPTOR CROSS-TALK; RECEPTORS, CANNABINOID; RECEPTORS, OPIOID; SUBSTANCE-RELATED DISORDERS;

EID: 9744279017     PISSN: 08920915     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevNeurobiol.v16.i12.170     Document Type: Review

References (94)

1. Akil, H., Owens, C., Gutstein, H., Taylor, L., Curran, E., Watson, S. (1998) Endogenous opioids: overview and current issues. Drug Alcohol Depend 51, 127-140.
2. Berrendero, F., Maldonado, R. (2002) Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol. Psychopharmacology (Berl) 163, 111-117.
3. Bloom, A.S., Dewey, W.L. (1978) A comparison of some pharmacological actions of morphine and delta9-tetrahydrocannabinol in the mouse. Psychopharmacology (Berl) 57, 243-248.
4. Bouaboula, M., Poinot-Chazel, C., Bourrie, B., Canat, X., Calandra, B., Rinaldi-Carmona, M., Le Fur, G., Casellas, P. (1995) Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J 312 (Pt 2), 637-641.
5. Campbell, F.A., Tramer, M.R., Carroll, D., Reynolds, D.J., Moore, R.A., McQuay, H.J. (2001) Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 323, 13-16.
6. Castane, A., Robledo, P., Matifas, A., Kieffer, B.L., Maldonado, R. (2003) Cannabinoid withdrawal syndrome is reduced in double mu and delta opioid receptor knockout mice. Eur J Neurosci 17, 155-159.
7. Corchero, J., Avila, M.A., Fuentes, J.A., Manzanares, J. (1997) Delta-9-tetrahydrocannabinol increases prodynorphin and proenkephalin gene expression in the spinal cord of the rat. Life Sci 61, L-43.
8. Corchero, J., Fuentes, J.A., Manzanares, J. (1999a) Chronic treatment with CP-55, 940 regulates corticotropin releasing factor and proopiomelanocortin gene expression in the hypothalamus and pituitary gland of the rat. Life Sci 64, 905-911.
9. Corchero, J., Fuentes, J.A., Manzanares, J. (2002) Gender differences in proenkephalin gene expression response to delta9-tetrahydrocannabinol in the hypothalamus of the rat. J Psychopharmacol 16, 283-289.
10. Corchero, J., Garcia-Gil, L., Manzanares, J., Fernandez-Ruiz, J.J., Fuentes, J.A., Ramos, J.A. (1998) Perinatal delta9-tetrahydrocannabinol exposure reduces proenkephalin gene expression in the caudate-putamen of adult female rats. Life Sci 63, 843-850.
11. Corchero, J., Manzanares, J., Fuentes, J.A. (1999b) Repeated administration of delta9-tetrahydrocannabinol produces a differential time related responsiveness on proenkephalin, proopiomelanocortin and corticotropin releasing factor gene expression in the hypothalamus and pituitary gland of the rat. Neuropharmacology 38, 433-439.
12. Corchero, J., Manzanares, J., Fuentes, J.A. (2001) Role of gonadal steroids in the corticotropin-releasing hormone and proopiomelanocortin gene expression response to Delta(9)-tetrahydrocannabinol in the hypothalamus of the rat. Neuroendocrinology 74, 185-192.
13. Corchero, J., Romero, J., Berrendero, F., Fernandez-Ruiz, J., Ramos, J.A., Fuentes, J.A., Manzanares, J. (1999c) Time-dependent differences of repeated administration with Delta9-tetrahydrocannabinol in proenkephalin and cannabinoid receptor gene expression and G-protein activation by mu-opioid and CB1-cannabinoid receptors in the caudate-putamen. Brain Res Mol Brain Res 67, 148-157.
14. Cravatt, B.F., Demarest, K., Patricelli, M.P., Bracey, M.H., Giang, D.K., Martin, B.R., Lichtman, A.H. (2001) Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 98, 9371-9376.
15. Degenhardt, L., Hall, W., Lynskey, M. (2001) The relationship between cannabis use and other substance use in the general population. Drug Alcohol Depend 64, 319-327.
16. Deutsch, D.G., Chin, S.A. (1993) Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 46, 791-796.
17. Deutsch, D.G., Ueda, N., Yamamoto, S. (2002) The fatty acid amide hydrolase (FAAH). Prostaglandins Leukot Essent Fatty Acids 66, 201-210.
18. Devane, WA., Hanus, L., Breuer, A., Pertwee, R.G., Stevenson, L.A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., Mechoulam, R. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949.
19. Dewey, W.L. (1986) Cannabinoid pharmacology. Pharmacol Rev 38, 151-178.
20. Elphick, M.R., Egertova, M. (2001) The neurobiology and evolution of cannabinoid signalling. Phil Trans R Soc Lond B Biol Sci 356, 381-408.
21. Fan, F., Compton, D.R., Ward, S., Melvin, L., Martin, B.R. (1994) Development of cross-tolerance between delta 9-tetrahydrocannabinol, CP 55, 940 and WIN 55.212. J Pharmacol Exp Ther 271, 1383-1390.
22. Felder, C.C., Veluz, J.S., Williams, H.L., Briley, E.M., Matsuda, L.A. (1992) Cannabinoid agonists stimulate both receptor- and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. Mol Pharmacol 42, 838-845.
23. Fergusson, D.M., Horwood, L.J. (2000) Does cannabis use encourage other forms of illicit drug use? Addiction 95, 505-520.
24. Fowler, C.J., Jacobsson, S.O. (2002) Cellular transport of anandamide, 2-arachidonoylglycerol and palmitoylethanolamide-targets for drug development? Prostaglandins Leukot Essent Fatty Acids 66, 193-200.
25. Freund, T.F., Katona, I., Piomelli, D. (2003) Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83, 1017-1066.
26. Fride, E. (2002) Endocannabinoids in the central nervous system-an overview. Prostaglandins Leukot Essent Fatty Acids 66, 221-233.
27. Fuentes, J.A., Ruiz-Gayo, M., Manzanares, J., Vela, G., Reche, I., Corchero, J. (1999) Cannabinoids as potential new analgesics. Life Sci 65, 675-685.
28. Gaetani, S., Cuomo, V., Piomelli, D. (2003) Anandamide hydrolysis: a new target for anti-anxiety drugs? Trends Mol Med 9, 474-478.
29. Gardell, L.R., Ossipov, M.H., Vanderah, T.W., Lai, J., Porreca, F. (2002) Dynorphin-independent spinal cannabinoid antinociception. Pain 100, 243-248.
30. Gardner, E.L., Lowinson, J.H. (1991) Marijuana's interaction with brain reward systems: update 1991. Pharmacol Biochem Behav 40, 571-580.
31. Ghozland, S., Matthes, H.W., Simonin, F., Filliol, D., Kieffer, B.L., Maldonado, R. (2002) Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J Neurosci 22, 1146-1154.
32. Glaser, S.T., Abumrad, N.A., Fatade, F., Kaczocha, M., Studholme, K.M., Deutsch, D.G. (2003) Evidence against the presence of an anandamide transporter. Proc Natl Acad Sci USA 100, 4269-4274.
33. Haney, M., Ward, A.S., Comer, S.D., Foltin, R.W., Fischman, M.W. (1999) Abstinence symptoms following oral THC administration to humans. Psychopharmacology (Berl) 141, 385-394.
34. Hescheler, J., Rosenthal, W., Trautwein, W., Schultz, G. (1987) The GTP-binding protein, Go, regulates neuronal calcium channels. Nature 325, 445-447.
35. Hillard, C.J., Edgemond, W.S., Jarrahian, A., Campbell, W.B. (1997) Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J Neurochem 69, 631-638.
36. Hine, B., Torrelio, M., Gershon, S. (1975) Interactions between cannabidiol and delta9-THC during abstinence in morphine-dependent rats. Life Sci 17, 851-857.
37. Hohmann, A.G., Herkenham, M. (2000) Localization of cannabinoid CB(1) receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. Synapse 37, 71-80.
38. Howlett, A.C., Fleming, R.M. (1984) Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol Pharmacol 26, 532-538.
39. Hutcheson, D.M., Tzavara, E.T., Smadja, C., Valjent, E., Roques, B.P., Hanoune, J., Maldonado, R. (1998) Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol. Br J Pharmacol 125, 1567-1577.
40. Iversen, L., Chapman, V. (2002) Cannabinoids: a real prospect for pain relief? Curr Opin Pharmacol 2, 50-55.
41. Kathuria, S., Gaetani, S., Fegley, D., Valino, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., La Rana, G., Calignano, A., Giustino, A., Tattoli, M., Palmery, M., Cuomo, V., Piomelli, D. (2003a) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9, 76-81.
42. Kathuria, S., Gaetani, S., Fegley, D., Valino, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., La Rana, G., Calignano, A., Giustino, A., Tattoli, M., Palmery, M., Cuomo, V., Piomelli, D. (2003b) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9, 76-81.
43. Kaymakcalan, S., Ayhan, I.H., Tulunay, F.C. (1977) Nalox-one-induced or postwithdrawal abstinence signs in delta9-tetrahydrocannabinol-tolerant rats. Psychopharmacology (Berl) 55, 243-249.
44. Koob, G.F. (1992) Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 13, 177-184.
45. Kouri, E.M., Pope, H.G., Jr., Lukas, S.E. (1999) Changes in aggressive behavior during withdrawal from long-term marijuana use. Psychopharmacology (Berl) 143, 302-308.
46. 1 receptor knockout mice. Science 283, 401-404.
47. 2 cannabinoid receptor-mediated peripheral antinociception. Pain 93, 239-245.
48. Maldonado, R., Valverde, O. (2003) Participation of the opioid system in cannabinoid-induced antinociception and emotional-like responses. Eur Neuropsychopharmacol 13, 401-410.
49. Mansour, A., Fox, C.A., Burke, S., Akil, H., Watson, S.J. (1995) Immunohistochemical localization of the cloned mu opioid receptor in the rat CNS. J Chem Neuroanat 8, 283-305.
50. Manzanares, J., Corchero, J., Fuentes, J.A. (1999a) Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of delta(9)-tetrahydrocannabinol in rats. Brain Res 839, 173-179.
51. Manzanares, J., Corchero, J., Romero, J., Fernandez-Ruiz, J.J., Ramos, J.A., Fuentes, J.A. (1998) Chronic administration of cannabinoids regulates proenkephalin mRNA levels in selected regions of the rat brain. Brain Res Mol Brain Res 55, 126-132.
52. Manzanares, J., Corchero, J., Romero, J., Fernandez-Ruiz, J.J., Ramos, J.A., Fuentes, J.A. (1999b) Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci 20, 287-294.
53. Manzanares, J., Uriguren, L., Rubio, G., Palomo, T. (2004) Role of endocannabinoid system in mental diseases. Neurotox Res 6, 1-12.
54. Mao, J., Price, D.D., Lu, J., Keniston, L., Mayer, D.J. (2000) Two distinctive antinociceptive systems in rats with pathological pain. Neurosci Lett 280, 13-16.
55. Martellotta, M.C., Cossu, G., Fattore, L., Cessa, G.L., Fratta, W. (1998) Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice. Neuroscience 85, 327-330.
56. 1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) 159, 379-387.
57. Martin, S., Manzanares, J., Corchero, J., Garcia-Lecumberri, C., Crespo, J.A., Fuentes, J.A., Ambrosio, E. (1999) Differential basal proenkephalin gene expression in dorsal striatum and nucleus accumbens, and vulnerability to morphine self-administration in Fischer 344 and Lewis rats. Brain Res 821, 350-355.
58. Martin, W.J., Coffin, P.O., Attias, E., Balinsky, M., Tsou, K., Walker, J.M. (1999) Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections. Brain Res 822, 237-242.
59. Matsuda, L.A., Lolait, S.J., Brownstein, M.J., Young, A.C., Bonner, T.I. (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564.
60. Mechoulam, R., Gaoni, Y. (1965) A total synthesis of DL-delta-1- tetrahydrocannabinol, the active constituent of hashish. J Am Chem Soc 87, 3273-3275.
61. Meng, I.D., Manning, B.H., Martin, W.J., Fields, H.L. (1998) An analgesia circuit activated by cannabinoids. Nature 395, 381-383.
62. Morita, K., North, R.A. (1982) Opiate activation of potassium conductance in myenteric neurons: inhibition by calcium ion. Brain Res 242, 145-150.
63. Munro, S., Thomas, K.L., Abu-Shaar, M. (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65.
64. Navarro, M., Carrera, M.R., Fratta, W., Valverde, O., Cossu, G., Fattore, L., Chowen, J.A., Gomez, R., del, A., I, Villanua, M.A., Maldonado, R., Koob, G.F., Rodriguez, d.F. (2001) Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci 21, 5344-5350.
65. Oliva, J.M., Ortiz, S., Palomo, T., Manzanares, J. (2003) Behavioural and gene transcription alterations induced by spontaneous cannabinoid withdrawal in mice. J Neurochem 85, 94-104.
66. Oviedo, A., Glowa, J., Herkenham, M. (1993) Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. Brain Res 616, 293-302.
67. Pertwee, R.G. (2001) Cannabinoid receptors and pain. Prog. Neurobiol. 63, 569-611.
68. Pertwee, R.G., Stevenson, L.A., Griffin, G. (1993) Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55, 940, WIN 55, 212-2 and anandamide. Br J Pharmacol 110, 1483-1490.
69. Pugh, G., Jr., Mason, D.J., Jr., Combs, V., Welch, S.P. (1997) Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55, 940 in the spinal cord. J Pharmacol Exp Ther 281, 730-737.
70. Reche, I., Fuentes, J.A., Ruiz-Gayo, M. (1996) A role for central cannabinoid and opioid systems in peripheral delta 9-tetrahydrocannabinol- induced analgesia in mice. Eur J Pharmacol 301, 75-81.
71. Rodriguez, d.F., Carrera, M.R., Navarro, M., Koob, G.F., Weiss, F. (1997) Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 276, 2050-2054.
72. Rodriguez, J.J., Mackie, K., Pickel, V.M. (2001) Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. J Neurosci 21, 823-833.
73. Romero, J., Berrendero, F., Manzanares, J., Perez, A., Corchero, J., Fuentes, J.A., Fernandez-Ruiz, J.J., Ramos, J.A. (1998) Time-course of the cannabinoid receptor down-regulation in the adult rat brain caused by repeated exposure to delta9-tetrahydrocannabinol. Synapse 30, 298-308.
74. Rubino, T., Patrini, G., Parenti, M., Massi, P., Parolaro, D. (1997) Chronic treatment with a synthetic cannabinoid CP-55, 940 alters G-protein expression in the rat central nervous system. Brain Res Mol Brain Res 44, 191-197.
75. Salio, C., Fischer, J., Franzoni, M.F., Mackie, K., Kaneko, T., Conrath, M. (2001) CB1-cannabinoid and mu-opioid receptor co-localization on postsynaptic target in the rat dorsal horn. Neuroreport 12, 3689-3692.
76. Sharma, S.K., Klee, W.A., Nirenberg, M. (1975) Dual regulation of adenylate cyclase accounts for narcotic dependence and tolerance. Proc Natl Acad Sci USA 72, 3092-3096.
77. Sipe, J.C., Chiang, K., Gerber, A.L., Beutler, E., Cravatt, B.F. (2002) A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc Natl Acad Sci USA 99, 8394-8399.
78. Stella, N., Schweitzer, P., Piomelli, D. (1997) A second endogenous cannabinoid that modulates long-term potentiation. Nature 388, 773-778.
79. Tanda, G., Munzar, P., Goldberg, S.R. (2000) Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat Neurosci 3, 1073-1074.
80. Tanda, G., Pontieri, F.E., Di Chiara, G. (1997) Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276, 2048-2050.
81. Tsou, K., Brown, S., Sanudo-Pena, M.C., Mackie, K., Walker, J.M. (1998) Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83, 393-411.
82. Valverde, O., Ledent, C., Beslot, F., Parmentier, M., Roques, B.P. (2000) Reduction of stress-induced analgesia but not of exogenous opioid effects in mice lacking CB1 receptors. Eur J Neurosci 12, 533-539.
83. Valverde, O., Maldonado, R., Valjent, E., Zimmer, A.M., Zimmer, A. (2000) Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice. J Neurosci 20, 9284-9289.
84. Vaughan, C.W., Connor, M., Bagley, E.E., Christie, M.J. (2000) Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Mol Pharmacol 57, 288-295.
85. Vela, G., Fuentes, J.A., Bonnin, A., Fernandez-Ruiz, J., Ruiz-Gayo, M. (1995a) Perinatal exposure to delta 9-tetrahydrocannabinol (delta 9-THC) leads to changes in opioid-related behavioral patterns in rats. Brain Res 680, 142-147.
86. Vela, G., Martin, S., Garcia-Gil, L., Crespo, J.A., Ruiz-Gayo, M., Javier Fernandez-Ruiz, J., Garcia-Lecumberri, C., Pelaprat, D., Fuentes, J.A., Ramos, J.A., Ambrosio, E. (1998) Maternal exposure to delta9-tetrahydrocannabinol facilitates morphine self-administration behavior and changes regional binding to central mu opioid receptors in adult offspring female rats. Brain Res 807, 101-109.
87. Vela, G., Ruiz-Gayo, M., Fuentes, J.A. (1995b) Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine. Neuropharmacology 34, 665-668.
88. von Sydow, K., Lieb, R., Pfister, H., Hofler, M., Sonntag, H., Wittchen, H.U. (2001) The natural course of cannabis use, abuse and dependence over four years: a longitudinal community study of adolescents and young adults. Drug Alcohol Depend 64, 347-361.
89. Walker, J.M., Hohmann, A.G., Martin, W.J., Strangman, N.M., Huang, S.M., Tsou, K. (1999) The neurobiology of cannabinoid analgesia. Life Sci 65, 665-673.
90. Walker, J.M., Huang, S.M., Strangman, N.M., Tsou, K., Sanudo-Pena, M.C. (1999) Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci USA 96, 12198-12203.
91. Wang, H., Gracy, K.N., Pickel, V.M. (1999) Mu-opioid and NMDA-type glutamate receptors are often colocalized in spiny neurons within patches of the caudate-putamen nucleus. J Comp Neurol 412, 132-146.
92. Wilson, R.I., Nicoll, R.A. (2002) Endocannabinoid signaling in the brain. Science 296, 678-682.
93. Zimmer, A., Valjent, E., Konig, M., Zimmer, A.M., Robledo, P., Hahn, H., Valverde, O., Maldonado, R. (2001) Absence of delta -9-tetrahydrocannabinol dysphoric effects in dynorphin-deficient mice. J Neurosci 21, 9499-9505.
94. Zuardi, A.W., Shirakawa, I., Finkelfarb, E., Karniol, I.G. (1982) Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) 76, 245-250.